Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101

SAN DIEGO, April 25, 2022 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced the formation of a Scientific Advisory Board (“SAB”) for its INBRX-101 program for the treatment of…

Click here to view original post